Omecamtiv mecarbil is a novel cardiac myosin activator that increases contractility in heart muscle through selectively activating the enzyme myosin ATPase. This results in increased cardiac contractility without impacting intracellular calcium, unlike many currently available inotropic agents. Changes in intracellular calcium are thought to be associated with adverse clinical effects in heart failure patients.
Cytokinetics’ strong strategic partnerships with larger companies such as Amgen has placed omecamtiv mecarbil in an ideal position to have optimum market penetration in the US, Japan, and EU. The drug’s ability to increase contractility without affecting intracellular calcium places it at a clear advantage to other inotropic agents such as digoxin, usage of which has declined due to safety issues associated with changes in intracellular calcium. Despite this promising mode of action, which may reduce side effects, Amgen will still need to provide strong clinical data in order to convince physicians of its benefit.
Omecamtiv mecarbil: Chronic heart failure (CHF)
List of Figures
Figure 1: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 3: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 4: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Omecamtiv mecarbil drug profile
Table 2: Omecamtiv mecarbil Phase III study in chronic heart failure
Table 3: Omecamtiv mecarbil Phase II data in chronic heart failure
Table 4: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26